Biofrontera Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Warrants WOBURN, MA., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (“Biofrontera” or the “Company”) (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of...

Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares Norwood, MA, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s leading...